Quotation request for +securities
Summary of the announcement
Name of entity
TELIX PHARMACEUTICALS LIMITED
Type of news
New announcement
Date of this announcement
Monday, January 31, 2022
The +securities to be listed are:
+Securities issued as part of one or more transactions previously announced to the market in an Appendix 3B
Total number of +stocks to be listed
|
ASX + security |
Number of +titles to |
||
|
coded |
Security description |
be quoted |
Date of issue |
|
TLX |
REGULAR FULLY PAID |
519 481 |
01/31/2022 |
See next page for full listing details
|
Quotation request for +securities |
1 / 6 |
Quotation request for +securities
Part 1 – Entity and listing details
1.1 Entity name
TELIX PHARMACEUTICALS LIMITED
We (the entity named above) request +listing of the following +securities and accept the questions set out in Appendix 2A of the ASX Listing Rules.
|
1.2 |
Registered number type |
Registration number |
|
ACN |
616620369 |
|
|
1.3 |
ASX issuer code |
|
|
TLX |
- The ad is New announcement
- Date of this announcement
31/1/2022
|
Quotation request for +securities |
2 / 6 |
Quotation request for +securities
Part 2 – Type of problem
2.1 The securities to be listed are:
+Securities issued as part of one or more transactions previously announced to the market in an Appendix 3B
|
Details of previous Annex 3B: |
||
|
Announcement date and |
Ad Title |
Selection of Annex 3B to submit a quote |
|
Time |
request |
|
|
24-Jan-2022 09:00 |
New – Proposed issue of securities – |
|
|
A location or other type of problem |
||
|
TLX |
||
2.3a.2 Are there other issuances of +securities still to take place to carry out the transaction(s) referred to in appendix 3B?
Yes
2.3a.3 Please provide details of other issues of securities + that have not yet taken place to complete the transaction(s) referred to in Annex 3B
The Company is seeking the listing of 519,481 shares which have been settled as of January 31, 2022. The Company will seek a separate listing for the balance of 160,519 shares to be issued under the Placement.
|
Quotation request for +securities |
3 / 6 |
Quotation request for +securities
Part 3A – number and type of securities + to be quoted when the issue has already been notified to the ASX in an annex 3B
Investment Details
|
alone |
ASX + security code and description |
|
TLX: REGULAR FULLY PAID |
|
|
Date of issue |
|
|
31/1/2022 |
|
|
use |
|
|
Release Schedule |
|
|
Provide a schedule for the distribution of new +titles according to the categories defined in the left column – |
|
|
including the number of beneficiaries and the total percentage of new+securities held by beneficiaries in each |
|
|
Category. |
|
personalfor |
Total percentage of +shares held |
|||
|
Number of +shares held |
Number of holders |
For example, to enter a value of 50% |
||
|
please enter 50.00 |
||||
|
1 – 1000 |
% |
|||
|
1,001 |
– 5,000 |
% |
||
|
5,001 |
– 10,000 |
% |
||
|
10,001 – 100,000 |
% |
|||
|
100,001 and more |
% |
|
Quotation request for +securities |
4 / 6 |
Quotation request for +securities
Problem details
Number of +securities to be listed
519 481
Are the +securities issued for cash consideration?
Yes
In what currency is the cash consideration paid? What is the issue price per +share?
|
AUD – Australian Dollar |
AU$7,700,000 |
Any other information that the entity wishes to provide on the +securities to be listed
|
Quotation request for +securities |
5 / 6 |
This is an excerpt from the original content. To continue reading it, go to the original document here.
Warning
Telix Pharmaceuticals Ltd. published this content on January 30, 2022 and is solely responsible for the information contained therein. Distributed by public, unedited and unmodified, on January 30, 2022 21:40:09 UTC.
Public now 2022
|
|
|
|
|
|
|
||||
|
||||
Technical Analysis Trends TELIX PHARMACEUTICALS LIMITED
| Short term | Middle term | Long term | |
| Tendencies | Bearish | Neutral | Bullish |
Evolution of the income statement
|
To sell  To buy |
|
| Medium consensus | TO BUY |
| Number of analysts | 5 |
| Last closing price |
$6.24 |
| Average target price |
$8.86 |
| Average Spread / Target | 42.0% |
